Last reviewed · How we verify
Nardostachys jatamansi
Nardostachys jatamansi is a Small molecule drug developed by Q.Mundewadi Ayurvedic Research & Charitable Trust. It is currently in Phase 2 development.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Nardostachys jatamansi |
|---|---|
| Sponsor | Q.Mundewadi Ayurvedic Research & Charitable Trust |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of the Efficacy of Dietary Supplementation in Targeting Sleep Quality (NutriSom-01B) (NA)
- The Effect of Valerian on Insomnia in Menopausal Women (NA)
- Feasibility Study on the Use of Redormin®500 on Day-time Cognition (PHASE4)
- Evaluation of a Combination of Plants in Anxiety-related Sleep Disorders: Randomized Trial Versus Placebo (NA)
- Clinical Trial on a Food Supplement With Melatonin and Herbal Products to Improve Sleep Quality (NA)
- Novel Formulation for Sleep Among People With Poor Sleep Quality (NA)
- Efficacy and Safety of Valerian Root Extract and Lavender Essential Oil Combination, Over 4 Weeks in Subjects With Sleep Complaints (PHASE2, PHASE3)
- Onnit Labs New Mood Supplementation in Healthy College Students (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nardostachys jatamansi CI brief — competitive landscape report
- Nardostachys jatamansi updates RSS · CI watch RSS
- Q.Mundewadi Ayurvedic Research & Charitable Trust portfolio CI
Frequently asked questions about Nardostachys jatamansi
What is Nardostachys jatamansi?
Who makes Nardostachys jatamansi?
What development phase is Nardostachys jatamansi in?
Related
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing